<DOC>
	<DOCNO>NCT00003543</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody find locate tumor cell either kill deliver tumor-killing substance without harm normal cell . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug combine chemotherapy monoclonal antibody therapy may kill tumor cell . PURPOSE : Phase I trial study effectiveness monoclonal antibody therapy plus combination chemotherapy treat patient advanced colorectal cancer .</brief_summary>
	<brief_title>Monoclonal Antibody Therapy Plus Combination Chemotherapy Treating Patients With Advanced Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Define toxicity maximum tolerate dose humanized monoclonal antibody A33 ( MOAB A33 ) combine carmustine , fluorouracil , vincristine , streptozocin patient advanced colorectal cancer . II . Determine effect chemotherapy human antihuman antibody response pharmacokinetics humanize MOAB A33 patient . III . Define humanize MOAB A33 dose phase II study . OUTLINE : This dose escalation study humanize monoclonal antibody A33 ( MOAB A33 ) . Patients receive humanize MOAB A33 IV week 14 week . Chemotherapy begin day 29 consist carmustine IV day 29-33 , fluorouracil IV day 29-33 64-68 , vincristine IV day 29 64 , streptozocin IV every 7 day , begin day 29 , 10 dos . Courses repeat every 14 week absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos humanize MOAB A33 . The maximum tolerate dose define dose 2 6 patient experience dose limit toxicity . PROJECTED ACCRUAL : There 3-18 patient accrue study 2-9 month .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Streptozocin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm unresectable stage IV colon rectal cancer fail conventional chemotherapy advance disease refuse treatment Measurable disease No liver involvement great 50 % No clinical evidence CNS tumor involvement PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 80100 % Life expectancy : At least 14 week Hematopoietic : WBC least 3,5000/mm3 Platelet count least 150,000/mm3 Hepatic : Bilirubin great 1.0 mg/dL Renal : Creatinine great 1.5 mg/dL Cardiovascular : No clinically significant cardiac disease ( New York Heart Association class III/IV heart disease ) Other : No positive human antimouse antibody titer No serious infection require treatment antibiotic No serious illness Not pregnant nursing Effective contraception require fertile patient PRIOR CONCURRENT THERAPY : Biologic therapy : No prior mouse monoclonal antibody antibody fragment , chimeric humanize antibody At least 4 week since prior immunotherapy Chemotherapy : No prior carmustine , fluorouracil , vincristine , streptozocin At least 4 week since prior chemotherapy Endocrine therapy : Not specify Radiotherapy : At least 4 week since prior radiotherapy Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
</DOC>